Multi-specific antibodies and methods of using thereof

A method for treating a cancer in a subject, said method comprising administering to the subject an effective amount of a pharmaceutical composition comprising a purified multi-specific antibody, wherein the multi-specific antibody comprises a tri-specific antibody monomer having a N-terminal and a C-terminal, comprising in tandem from the N-terminal to the C-terminal,

• a first scFv domain at the N-terminal, comprising the following pairs of amino acid sequences:
• SEQ ID NOs:
• (2 and 4), (6 and 8), or (10 and 12), having the binding specificity against ROR1,
• SEQ ID NOs:
• (14 and 16), having the binding specificity against PD-L1,
• SEQ ID NOs:
• (40 and 42), having the binding specificity against EGFRvIII, or
• SEQ ID NOs:
• (44 and 46), having the binding specificity against CD19,
• a Fab domain, having a binding specificity against PD-L1, EGFRvIII, or CD19,
• a Fc domain, and
• a second scFv domain at the C-terminal, having a binding specificity against CD3 and comprising the following pairs of sequences SEQ ID NOs:
• (18 and 20), (22 and 24), (26 and 28), (30 and 32), or (30 and 34),
• wherein the first scFv domain, the Fab domain, and the second scFv domain each has a binding specificity against a different antigen, and wherein the cancer comprises cells expressing ROR1, PD-L1, EGFRvIII, or CD19.